首页> 美国卫生研究院文献>British Heart Journal >Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG
【2h】

Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG

机译:给予链激酶或抗阿曲普酶后长达30个月的急性心肌梗死患者链激酶抵抗滴度监测及相关研究以测量特异性抗链激酶IgG

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective—To examine the induction of antistreptokinase antibodies after giving streptokinase or anistreplase to patients with acute myocardial infarction.Design—Patients were randomly allocated to receive either 1·5 × 106 IU, streptokinase or 30U anistreplase in a double blind study. Blood samples were collected immediately before treatment and subsequently at intervals up to 30 months; plasma samples were assayed for streptokinase resistance titre (functional assay) and streptokinase binding by IgG (microradioimmunoassay).Setting—Cardiology department in a general hospital.Patients—128 consecutive eligible patients. Samples were collected for up to one year according to a prospective design: a subsection of 47 patients was selected for intensive study over the first 14 days. After one year, all available patients (67) were sampled on one further occasion.Results—Antibody responses to streptokinase and anistreplase were similar. Streptokinase resistance titres exceeded pretreatment concentrations five days after dosing, and values peaked at 14 days. By 12 months after dosing, 92% of resistance titres (n = 84) had returned to within the pretreatment range. Antistreptokinase IgG concentrations also exceeded baseline concentrations within five days and peaked at 14 days. Half of the individual values had returned to within the pretreatment range by 12 months (n = 84) and 89% by 30 months (n = 18).Conclusion—Although we cannot be sure of the clinical significance, because of the increased likelihood of resistance due to antistreptokinase antibody, streptokinase and anistreplase may not be effective if administered more than five days after an earlier dose of streptokinase or anistreplase, particularly between five days and 12 months, and increased antistreptokinase antibody may increase the risk of allergic-type reactions.
机译:目的—研究急性心肌梗死患者给予链激酶或抗阿斯普酶后抗链激酶的抗体的产生。设计—患者随机分配接受1·5×10 6 IU,链激酶或30U阿尼普酶治疗。一项双盲研究。在治疗前立即采血,随后间隔30个月;通过IgG检测血浆样品的链激酶抗性滴度(功能测定)和链激酶的结合(微量放射免疫测定)。设置-综合医院心脏病科。患者-连续入选的128例患者。根据前瞻性设计,样本收集了长达一年的时间:选择了47名患者的一个小部分进行头14天的深入研究。一年后,再次对所有可用的患者(67)进行了采样。结果—对链激酶和抗阿昔普酶的抗体反应相似。给药后五天,链激酶抵抗力滴度超过了治疗前的浓度,在14天达到峰值。给药后12个月,抗药性滴度(n = 84)已恢复至预处理范围内的92%。抗链激酶激酶IgG的浓度在5天内也超过了基线浓度,并在14天内达到峰值。到12个月时(n = 84),一半的个体值恢复到治疗前的范围内;到30个月时(n = 18),个体值的恢复到89%的范围内。尽管我们不能确定其临床意义,因为增加了治疗的可能性。如果在较早剂量的链激酶或抗阿曲肽酶后超过5天给药,尤其是5天至12个月之间,抗链激酶抗体,链激酶和抗阿曲肽酶引起的耐药性可能无效,并且抗链激酶蛋白抗体增加可能会增加过敏性反应的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号